Session No LBCT 1					
	Friday, June 14, 2024, 08:00-09:00 Hall A				
THEME			Late Breaking Clinical Trials #1		
La	anguage		English		
MOD	ERATOR		Osamu lida		
MOD	ERATOR		Sabine Steiner		
	PANEL		Masahiko Fujihara		
	PANEL		Ralf Langhoff		
	PANEL		Kazunori Horie		
	PANEL		Brian DeRubertis		
	PANEL		Steven Kum		
Time	Speech (min)	QA (min)	Title and Speaker		
08:00-	5	3	One-year outcomes following a novel drug-eluting balloon "Luminor" for femoropopliteal lesion ~ SOL JAPAN Study~		
			Yoshimitsu Soga		
08:08-	5	3	Two-years result from the REAL-DES study		
			Tsuyoshi Shibata		
	5	3	24-month results from SELUTION SFA Japan trial -Safety and		
08:16-			efficacy of a novel sirolimus-coated balloon for the treatment		
			of femoropopliteal lesions in Japanese population-		
			Osamu lida		
08:24-	5	5 3	FINAL 5-year data of the T.I.N.T.I.N. Trial: Luminor DCB and involution stent in TASC C and D femoropopliteal atherosclerotic disease		
			Koen Deloose		
	_	_	Three-year result from the CAULIFLOWER study		
08:32-	5	3	Naoki Fujimura		
			Effectiveness and Safety of Mechanical Thrombectomy and		
08:40-	5	•	Thrombo-aspiration for Patients with Acute Limb Ischemia:		
		3	a Systematic Review and Meta-analysis		
			Yann Gouëffic		
		5 3	Safety of the orbital atherectomy in FP lesions:		
08:48	5		Preliminary result of the KAIZEN trial		
			Hiroyoshi Yokoi		
_					

		Session No A1		
The		lay, June 14, 2024, 9:10-10:10 Hall A		
The		PAD Main Live Demonstration #1		
Sub-th		Leave the right thing behind		
Co-sp	onsor: Cook i	Medical Japan G.K. / KANEKA MEDICAL PRODUCTS.		
	Language	Forelish		
	Language	English		
	MODERATOR	Osamu lida		
	MODERATOR	Hiroyoshi Yokoi		
	FACILITATOR	Tatsuro Takei		
	PANEL	Yann Gouëffic		
	PANEL	Sabine Steiner		
	PANEL	Jackie Pei Ho		
	PANEL	Tomoyasu Sato		
	PANEL	Shigeo Ichihashi		
-	PANEL	Shannon D. Thomas		
-	PANEL	Brian DeRubertis		
	Operator	Tatsuya Nakama		
Tokyo Bay Mo	edical Center	CASE 01		
Theme;				
Short	Speech	T. 10 10 1		
Lecture	(min)	Title and Speaker		
	г	The 3-year result of the REALDES study		
1.	5	Tsuyoshi Shibata		
		Durable results with Zilver PTX stent implantation for		
		complex femoropopliteal disease: insights from clinical		
2.	5	trials and daily practice		
		Sabine Steiner		
		Deciphering PTX Safety: Comprehensive Insights from		
2				
3.	5	Multi-Patient Data Analyses		
		Yann Gouëffic		

		Session No A2			
Friday, June 14, 2024, 10:20-11:20 Hall A					
The	eme	PAD Main Live Demonstration #2			
Sub-t	heme				
Co-sponsor: Cordis / Philips Japan, Ltd.					
	Language	English			
	MODERATOR	Osamu lida			
	MODERATOR	Shinsuke Kikuchi			
	FACILITATOR	Akiko Tanaka			
	PANEL	George Adams			
	PANEL	Donghoon Choi			
	PANEL	Bryan Yan			
	PANEL	Kazuki Tobita			
	PANEL	Naoki Fujimura			
	PANEL	Wuttichai Saengprakai			
	PANEL	Uei Pua			
	Operator	Daizo Kawasaki			
Morinor	miya Hospital	CASE 02			
Theme;					
Short	Speech	Title and Speaker			
Lecture	(min)	Title and Speaker			
		Unlocking the Potential of TRI Through COMFORT Registry			
1.	5	Insights: Strategic Utilization for Future Interventions			
		Masato Nakamura			
		Choosing Radial Access: Insights and Evidence from a			
2.	. 5	Multicenter Study			
		Amane Kozuki			
		Revolutionizing Lower Limb Interventions: Insights from			
3.	5	Hong Kong's Radial-to-Peripheral Approach			
		Bryan Yan			

		Session No A3
	Frida	ay, June 14, 2024, 13:00-14:00 Hall A
The		PAD Main Live Demonstration #3
Sub-t	heme	
	Co-s	sponsor: Boston Scientific Japan K.K.
	Language	English
	MODERATOR	Yoshimitsu Soga
	MODERATOR	Shigeo Ichihashi
	FACILITATOR	Naoki Yoshioka
	PANEL	Sorracha Rookkapan
	PANEL	Andrej Schmidt
	PANEL	Veera Suwanruangsri
	PANEL	Shuichi Seki
	PANEL	Yoshinori Tsubakimoto
	PANEL	Koen Deloose
	PANEL	Eric Ducasse
	Operator	Tatsuya Nakama
Tokyo Bay M	edical Center	CASE 03
Theme;		
Short Lecture	Speech (min)	Title and Speaker
1.	5	Insights from the several nation wide registry in Japan: What should we learn from the current evidence? Yoshimitsu Soga
		Two-year result from the PROSPECT MONSTER study
2.	5	Yo Iwata
3.	5	Safety of the Double Drug Dose for Femoropopliteal Interventions: Provisional Stenting with Eluvia Drug-Eluting Stent after Paclitaxel-Coated Balloon Angioplasty Sabine Steiner
-		

	Session No A4				
	Frida	ay, June 14, 2024, 14:10-15:10 Hall A			
Thei	me	PAD Main Live Demonstration #4			
Sub-th	neme				
	Co-	-sponsor: Medtronic Japan Co., Ltd.			
	Language	English			
	MODERATOR	Kenji Suzuki			
	MODERATOR	Masato Nakamura			
	FACILITATOR	Takahiro Tokuda			
	PANEL	Trakarn Chaivanit			
	PANEL	Peter Schneider			
	PANEL	Nattawut Puangpunngam			
	PANEL	Yuki Imoto			
	PANEL	Jaroen Cheewinmethasir			
	PANEL	Craig M. Walker			
	PANEL	Parichart Tanimit			
	Operator	Daizo Kawasaki			
Morinon	niya Hospital	CASE 04			
Theme;					
Short	Speech	Title and Speaker			
Lecture	(min)	пие апа эреакет			
		The Risks of Paclitaxel Safety Concerns: Why There Are			
1.	5	Reasons Not to Use It			
		Peter Schneider			
		Expanding the Horizons in DCB Treatment: When Technique			
2.	5	Transcends Technology (Insights from EAGLE study)			
		Naoki Hayakawa			
	5	Atherectomy plus DCB for complex femoropopliteal lesions			
3.		John R. Laird			

	Session No A5				
	Frid	ay, June 14, 2024, 16:00-17:00 Hall A			
Thei	me	PAD Main Live Demonstration #5			
Sub-th	ieme				
Co-	sponsor: W. l	L. Gore & Associates G.K. / NIPRO CORPORATION			
	Language	English			
	MODERATOR	Masahiko Fujihara			
	MODERATOR	Kazushi Urasawa			
	FACILITATOR	Ryoichi Kyuragi			
	PANEL	Chia-Hsun Lin			
	PANEL	Ralf Langhoff			
	PANEL	Hiroki Takahashi			
	PANEL	Eiji Karashima			
	PANEL	Wuttichai Saengprakai			
	PANEL	Chung-Dann Kan			
	PANEL	Hsuan Li Huang			
	Operator	Tatsuya Nakama			
Tokyo Bay Me	edical Center	CASE 05			
Theme;					
Short	Speech	Title and Charles			
Lecture	(min)	Title and Speaker			
4	F	What should we learn from the RELINE MAX study?			
1.	5	Chia-Hsun Lin			
	5	Breaking Down the Rumors: The True Limits of DCB			
2.		Taku Toyoshima			
	5	Stentgraft Solutions: Key Insights from the COYWOLF Study			
3.		Yo Iwata			

Session No A6				
	Frid	ay, June 14, 2024, 17:10-18:10 Hall A		
Thei	me	PAD Main Live Demonstration #6		
Sub-th	neme	The future of the drug technology for FP lesions		
	(Co-sponsor: Concept Medical Inc.		
	Language	English		
	MODERATOR	Masahiko Fujihara		
	MODERATOR	Steven Kum		
	FACILITATOR	Yo Iwata		
	PANEL	Ramon L. Varcoe		
	PANEL	Young guk Ko		
	PANEL	Andrej Schmidt		
	PANEL	Takuya Haraguchi		
	PANEL	Sahil Parikh		
	PANEL	Chung-Ho Hsu		
	PANEL	Taku Kato		
	Operator	Edward Choke		
Sengk	kang General	CASE 06		
-	Hospital			
Theme;				
Short	Speech	Title and Speaker		
Lecture	(min)	True and Speaker		
		Drug Technology in BTK Arteries: Navigating the Limits of		
1.	5	PTX and Unlocking the Potential of Limus		
		Sahil Parikh		
		Optimizing Lesion Preparation Before Applying the Drug		
2.	. 5	technologies: Identifying the Best Approach		
		Takuya Haraguchi		
		What should we learn from the SIRONA trial?		
3.	5	Andrej Schmidt		
		, i.i.d. oj odininat		

			Session No LBCT2	
Sat		Sat	turday, June 15, 2024, 08:00-09:00 Hall A	
THEME			Late Breaking Clinical Trials #2	
Sub	-THEME		3 3 3 3	
La	anguage		English	
	ERATOR		Tatsuya Nakama	
MOD	ERATOR		Yann Gouëffic	
-	PANEL		Terutoshi Yamaoka	
	PANEL		Donghoon Choi	
	PANEL		Shinsuke Kikuchi	
	PANEL		George Liell Adams	
	PANEL		Marianne Brodmann	
Time	Speech	QA	Title and Speaker	
Time	(min)	(min)	Title and Speaker	
08:00-	5	2	Insights from the ASPARAGUS study	
			Mitsuyoshi Takahara	
08:07-	5	2	Three-year Outcomes from the POPCORN Registry	
			Masashi Fukunaga	
	5	5 2	Recurrent patterns and clinical outcomes after drug-coated	
08:14-			balloon angioplasty for femoropopliteal artery lesions	
			Naoki Yoshioka	
			ASsessment of tHerapy for latrogenic pseudoaneurysm	
08:21-	5	2	including BAlloon-assisted hemostasis and conveNtional	
00.21	•		sUrgical repair: SHIBAINU retrospective multicenter study	
			Kazuki Tobita	
			Clinical outcomes following Drug-eluting device for	
08:28-	5	5 2	femoropopliteal lesion : CILANTRO registry	
			Yusuke Tomoi	
08:35-	5	5 2	Insights from the INFINITY-ISR study	
		<u>~</u>	Tatsuya Nakama	

		Session No A7	
Saturday, June 15, 2024, 9:10-10:10 Hall A			
Thei	me	PAD Main Live Demonstration #7	
Sub-th	ieme		
	Co	-sponsor: Medtronic Japan Co., Ltd.	
	Language	English	
	MODERATOR	Tatsuya Nakama	
	MODERATOR	Masato Nakamura	
	FACILITATOR	Sayaka Funabashi	
	PANEL	John R. Laird	
	PANEL	Nattawut Puangpunngam	
	PANEL	Ahmed Rafizi Hariz Ramli	
	PANEL	Gerard Goh	
	PANEL	Amane Kozuki	
	PANEL	Riho Suzuki	
	PANEL	Takafumi Fujita	
	PANEL	Parichart Tanimit	
	Operator	Osamu lida	
Kokura Memo	rial Hospital	CASE 07	
Theme;			
Short Lecture	Speech (min)	Title and Speaker	
1.	5	Drug coated balloons for femoropopliteal disease - what's the latest.	
		John R. Laird	
2.	5	Deciphering IVUS-Detected Dissections: Delineating the Threshold of Malignancy	
		Amane Kozuki	
		Randomized trial comparing a stent-avoiding with a stent-	
3.	5	preferred strategy in complex femoropopliteal lesions (BEST SFA study): 2 year outcome data	
		Sabine Steiner	

		Cossion No AO		
Session No A8				
		day, June 15, 2024, 10:20-11:20 Hall A		
Then		PAD Main Live Demonstration #8		
Sub-th				
	Co-spo	onsor: Medicon, Inc / Philips Japan, Ltd.		
	Language	English		
	ODERATOR	Makoto Sugihara		
	ODERATOR	Hiroshi Ando		
	ACILITATOR	Kenji Ogata		
	PANEL	Naoto Inoue		
	PANEL	I-Ming Chen		
	PANEL	Mariano Palena		
	PANEL	Andrej Schmidt		
	PANEL	Yusuke Tomoi		
	PANEL	Takenobu Shimada		
	PANEL	Sorracha Rookkapan		
	PANEL	Su Hong Kim		
	Operator	Masahiko Fujihara		
Kishiwada	Tokushukai	CASE 08		
	Hospital			
Theme;				
Short	Speech	Title and Speaker		
Lecture	(min)	Thie and Speaker		
		Maximizing Impact with UltraScore: Unveiling the Pinnacle		
1.	5	of Scoring Systems		
		Mariano Palena		
		Insights from the SAFE registry; what is the definition of the		
2.	5	"optimal" vessel prep		
		Andrej Schmidt		
	5	When should we set the stent in femoropopliteal segment?		
3.		Yusuke Tomoi		

		Session No A9			
	Saturday, June 15, 2024, 12:40-13:40 Hall A				
The	eme	PAD Main Live Demonstration #9			
Sub-t	heme				
	Co-s	sponsor: Boston Scientific Japan K.K.			
		NIPRO CORPORATION			
	Language	English			
	MODERATOR	Kenji Suzuki			
	MODERATOR	Nobuyoshi Azuma			
	FACILITATOR	Sayaka Funabashi			
	PANEL	Naoto Inoue			
	PANEL	Saritphat Orrapin			
	PANEL	Yin Chun Skyi Pang			
	PANEL	Shigeo Ichihashi			
	PANEL	Takehiro Yamada			
	PANEL	Darryl Lim Mingjun			
	PANEL	YueHong Zheng			
	PANEL	Nicolas Louis			
	Operator	Masahiko Fujihara			
Kishiwad	la Tokushukai	CASE 09			
	Hospital				
Theme;					
Short	Speech	Title and Speaker			
Lecture	(min)	Title and Speaker			
		Navigating DCB Limitations and DES Applications through			
1.	5	IVUS Insights			
		Kazunori Horie			
		IVUS in peripheral interventions: from the evidence-based			
2.	5	review to clinical practice in Thailand			
		Saritphat Orrapin			
		DES/DCB/BMS: What Do Single-Arm and Comparative Trials			
3.	5	Teach Us			
	-	Marianne Brodmann			

Session No A10				
	Satur	day, June 15, 2024, 13:50-14:50 Hall A		
The	me	PAD Main Live Demonstration #10		
Sub-th	neme			
	Co-sponso	or: Philips Japan, Ltd. / Medico's Hirata Inc.		
	Language	English		
	MODERATOR	Tatsuya Nakama		
	MODERATOR	Kazushi Urasawa		
	FACILITATOR	Kei Ichihashi		
	PANEL	Craig M. Walker		
	PANEL	Koen Deloose		
	PANEL	Shannon D. Thomas		
	PANEL	Masataka Yoshinaga		
	PANEL	Su Hong Kim		
	PANEL	Yoshito Yamamoto		
	PANEL	Prakash Krishnan		
	Operator	Yoshimitsu Soga		
Kokura Memo	orial Hospital	CASE 10		
Theme;				
Short Lecture	Speech (min)	Title and Speaker		
1.	5	Optimizing Strategies for Stent Failure in Femoropopliteal Lesions: A Comprehensive Approach		
		Craig M. Walker		
2.	5	FINAL 5-year data of the T.I.N.T.I.N. Trial: Luminor DCB and involution stent in TASC C and D femoropopliteal atherosclerotic disease		
		Koen Deloose		
3.	5	Insights from the INFINITY ISR registry; Does the OFDI change the "games" in ISR lesions?		
		Tatsuya Nakama		

Session No A11			
Saturday, June 15, 2024, 15:40-16:40 Hall A			
Theme		PAD Main Live Demonstration #11	
Sub-theme			
Co-sponsor: W. L. Gore & Associates G.K. / KANEKA MEDICAL PRODUCTS.			
Language		English	
MODERATOR		Takao Ohki	
MODERATOR		Tatsuya Nakama	
FACILITATOR		Taku Kato	
PANEL		Edward Choke	
PANEL		Ralf Langhoff	
PANEL		Chung-Dann Kan	
PANEL		Yuki Shima	
PANEL		Donghoon Choi	
PANEL		Shinsuke Kikuchi	
PANEL		I-Ming Chen	
Operator		Masahiko Fujihara	
Kishiwada Tokushukai		CASE 11	
Hospital			
Theme;			
Short	Speech	Title and Speaker	
Lecture	(min)	Thie and Speaker	
1.	5	Insights from the AVOCAD and AVOCAD II	
		Yusuke Tomoi	
2.	5	Delivering the Most Reliable Stents from the Safest Access	
		Sites	
		Kenji Suzuki	
3.	5	How should we treat Recurrence of AI lesions: Insights from	
		the multicenter study?	
		Takahiro Tokuda	
-			

Socian No A12				
Session No A12				
		day, June 15, 2024, 16:50-17:50 Hall A		
Theme		PAD Main Live Demonstration #12		
Sub-theme Co. changer: KANEKA MEDICAL PRODUCTS				
Co-sponsor: KANEKA MEDICAL PRODUCTS.				
Longuage		English		
Language		English Nahuhina Guarratau		
MODERATOR		Nobuhiro Suematsu		
MODERATOR		Makoto Sugihara		
FACILITATOR		Taku Toyoshima		
PANEL		Roberto Ferraresi		
PANEL		Shannon D. Thomas		
PANEL		Steven Kum		
PANEL		Yusuke Sato		
PANEL		Hideyuki Takimura		
	PANEL	Hsuan Li Huang		
	PANEL	Pankaj Jha		
Operator		Yoshimitsu Soga		
Kokura Memorial Hospital		CASE 12		
Theme;				
Short	Speech	Title and Speaker		
Lecture	(min)			
1.	5	Assessing the Necessity of Drug Technology in BTK Disease:		
		A Comprehensive Overview		
		Yo Iwata		
2.	5	Transforming the Horizon: The Impact of the LIFE BTK Trial		
		Results in CLTI management		
		Ramon L. Varcoe		
3.	5	High-pressure balloon and block technique is the evolution		
		for the BTK interventions		
		Steven Kum		